Skip to main content

RCUS

Stock
Health Care
Biotechnology

Performance overview

RCUS Price
Price Chart

Forward-looking statistics

Beta
1.34
Risk
61.87%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Company info

SectorHealth Care
IndustryBiotechnology
Employees544
Market cap$1.4B

Fundamentals

Enterprise value-$54.1M
Revenue$141.0M
Revenue per employee
Profit margin-277.30%
Debt to equity15.25

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$4.23
Dividend per share
Revenue per share$1.51
Avg trading volume (30 day)$10M
Avg trading volume (10 day)$10M
Put-call ratio

Macro factor sensitivity

Growth-0.1
Credit+6.5
Liquidity-2.7
Inflation-5.0
Commodities-0.9
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio-1.81
Price to sales6.36
P/E Ratio-1.81
Enterprise Value to Revenue-0.38
Price to book1.69

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.

Zacks Investment Research (May 6, 2025)
Why Are Arcus Biosciences Shares Trading Higher Today?

Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT molecules, domvanalimab, and AB308, as well as etrumadenant and quemliclustat. Under the terms Agreement, Arcus will receive option payments totaling $725 million for the three options that Gilead is exercising today.

Benzinga (November 18, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free